ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

J. U. Holle; W. L. Gross

doi:10.1016/j.jaut.2009.02.019

ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

J. U. Holle^*, W. L. Gross

^*Corresponding author for this work

Department of Rheumatology and Clinical Immunology

17 Citations (Scopus)

Abstract

A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review.

Original language	English
Journal	Journal of Autoimmunity
Volume	32
Issue number	3-4
Pages (from-to)	163-171
Number of pages	9
ISSN	0896-8411
DOIs	https://doi.org/10.1016/j.jaut.2009.02.019
Publication status	Published - 05.2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1016/j.jaut.2009.02.019

Cite this

@article{4403848ea4a442f7aedb53daaf261437,

title = "ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy",

abstract = "A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review.",

author = "Holle, \{J. U.\} and Gross, \{W. L.\}",

year = "2009",

month = may,

doi = "10.1016/j.jaut.2009.02.019",

language = "English",

volume = "32",

pages = "163--171",

journal = "Journal of Autoimmunity",

issn = "0896-8411",

publisher = "Academic Press",

number = "3-4",

}

TY - JOUR

T1 - ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

AU - Holle, J. U.

AU - Gross, W. L.

PY - 2009/5

Y1 - 2009/5

N2 - A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review.

AB - A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review.

UR - https://www.scopus.com/pages/publications/67349214603

U2 - 10.1016/j.jaut.2009.02.019

DO - 10.1016/j.jaut.2009.02.019

M3 - Journal articles

C2 - 19345067

AN - SCOPUS:67349214603

SN - 0896-8411

VL - 32

SP - 163

EP - 171

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

IS - 3-4

ER -

ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this